The cancer patient’s own drug sensitivity model

The cancer patient’s own drug sensitivity model: researchers from the Lothe lab and collaborators recently published a paper in Clinical Cancer Research describing ex vivo patient-derived organoids from colorectal liver metastases in a heterogeneity context. Drs. Jarle Bruun, Kushtrim Kryeziu and Peter W. Eide (photo) were shared 1st authors, and have established the PDO lineages and drug screen analyses.

Jørgen Smeby the first to defend his PhD digitally at the Institute for Cancer Research

The first digital PhD defence at the Institute for Cancer Research was held on the 20th of April 2020. Dr. Jørgen Smeby defended his thesis "Molecular subtype-dependent impact of driver mutations in colorectal cancer" submitted to the Faculty of Medicine, University of Oslo. The work was performed in the Lothe lab at the Institute for Cancer Research and the K. G. Jebsen Colorectal Cancer Research Centre.

Latest publications

Eilertsen et al. 2020. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. 469: 246-255 Araghi et al. 2020. Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut [Online ahead of print] Lopes et al. 2020. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer [Online ahead of print] Bruun et al. 2020. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin. Cancer Res. [Online ahead of print] Brunsell et al. 2020. High concordance and negative prognostic impact of RAS/BRAF/PIK3CA mutations in multiple resected colorectal liver metastases. Clin. Colorectal Cancer [Online ahead of print] All publications